Aratana therapeutics, inc. (PETX)
Income statement / Quarterly
Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12Jun'12
Revenues
Total revenues

7,360

4,906

21,555

4,908

4,043

10,457

6,163

5,158

3,795

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Licensing and collaboration revenue

-

-

-

-

-

-

-

-

-

-

0

38,000

151

-

-

-

-

-19

43

300

176

-

-

-

0

-

-

Product sales

-

-

-

-

-

-

-

-

-

-

40

47

21

63

229

230

156

-

-

-

-

-

-

-

0

-

-

Total revenues

-

-

-

-

-

-

-

-

-

-

40

38,047

172

63

229

230

156

248

43

300

176

-

-

-

0

0

0

Costs and expenses
Cost of product sales

1,519

-

2,172

-

536

-

3,690

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product sales

-

-

-

1,305

-

-

-

3,691

3,094

-

286

1,741

19

8

138

109

110

-

-

-

-

-

-

-

0

-

-

Royalty expense

1,692

798

1,346

915

806

704

441

353

323

49

19

20

18

18

23

23

20

20

17

17

18

-

-

-

0

-

-

Research and development

1,775

-

-

-

2,205

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

1,507

1,576

-

3,552

3,220

3,700

4,654

9,076

5,334

5,303

10,749

6,465

6,197

6,081

6,221

6,035

6,078

4,300

3,572

3,108

3,234

2,469

2,114

1,658

1,929

Selling, general and administrative

9,193

7,362

7,010

6,709

7,699

7,574

6,910

6,918

7,495

7,719

6,924

6,148

6,551

5,758

4,997

4,879

4,185

5,025

3,897

4,404

4,612

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,427

1,258

1,226

1,065

623

In-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

0

500

657

-

0

-

-

-

-

Amortization of intangible assets

143

129

129

129

130

115

85

86

64

98

91

95

95

95

483

483

483

189

581

582

539

-

-

-

0

-

-

Impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

2,780

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development

-

0

0

0

500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43,398

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

14,322

12,626

12,164

10,634

11,876

25,305

14,346

14,748

15,630

23,197

12,654

16,087

17,432

12,344

55,236

11,575

11,019

12,602

10,573

9,803

9,398

8,176

4,661

3,727

3,340

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,723

2,552

Loss from operations

-6,962

-7,720

9,391

-5,726

-7,833

-14,848

-8,183

-9,590

-11,835

-22,905

-12,614

21,960

-17,260

-12,281

-55,007

-11,345

-10,863

-12,354

-10,530

-9,503

-9,222

-8,053

-4,661

-3,727

-3,340

-2,723

-2,552

Other income (expense)
Interest income

174

225

159

141

141

138

138

88

85

109

116

83

77

42

33

43

71

65

31

13

14

24

26

22

3

5

3

Interest expense

-

1,034

716

788

853

880

870

871

860

842

859

846

849

924

226

217

218

292

222

218

328

250

80

78

24

-

-

Other income (expense), net

1

-105

-1

0

-3

-8

-5

-7

-2

305

-14

-1

-35

-1

0

3,176

1,965

2,445

-10

95

-243

23

44

343

68

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

81

-

Total other income (expense)

175

-914

-558

-647

-715

-750

-737

-790

-777

-428

-757

-764

-807

-883

-193

3,002

1,818

2,218

-201

-110

-557

-203

-10

287

47

86

3

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,164

-55,200

-8,343

-9,045

-10,136

-10,731

-9,613

-9,779

-8,256

-4,671

-3,440

-3,293

-

-

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-309

-758

-360

-271

120

-601

-335

-627

-12,722

0

0

0

-

-

Net income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,983

-

-

-

-

-

-

-

-

-

-

-

Net loss

-6,787

-8,634

8,833

-6,373

-8,548

-15,598

-8,920

-10,380

-12,612

-23,333

-13,371

21,196

-18,067

-12,855

-54,442

-7,983

-8,774

-10,256

-10,130

-9,278

-9,152

-

-

-3,440

-3,293

-2,637

-2,549

Net loss per share, basic and diluted

-0.14

-0.18

0.19

-0.14

-0.19

-0.36

-0.21

-0.26

-0.34

-0.66

-0.38

0.61

-0.52

-0.38

-1.58

-0.23

-0.26

-0.29

-0.35

-0.32

-0.34

8.94

-0.22

-4.62

-4.73

-9.64

-10.21

Net income attributable to participating securities

-

-

-

-

-

-

-

-

-

-

-

20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unaccreted dividends on convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

808

773

-527

-522

Net income (loss) attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

21,176

-

-

-

-

-

-

-

-

-

-

-4,671

-4,248

-4,066

-3,164

-3,071

Weighted average shares outstanding, basic and diluted

48,277

-

-

46,258

44,788

-

-

40,206

36,711

-

35,092

-

34,653

-

34,405

-

34,193

34,194

29,348

28,761

26,765

21,652

20,806

918

860

328

300

Weighted average shares outstanding, basic

-

-

47,310

-

-

-

42,445

-

-

-

-

34,762

-

-

-

34,278

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares outstanding, diluted

-

-

47,485

-

-

-

42,445

-

-

-

-

34,938

-

-

-

34,278

-

-

-

-

-

-

-

-

-

-

-

Licensing and Collaboration [Member]
Total revenues

3,387

-

-

-

1,706

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product Sales [Member]
Total revenues

3,973

-

-

-

2,337

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-